This study investigates the effectiveness, safety, and tolerability of an investigational medication for patients with relapsed or refractory blood cancers, which are also known as hematologic malignancies. These are cancers that affect the blood, bone marrow, and lymph nodes. The study aims to understand how well the medication works and how safe it is for patients.
Participants in the study will undergo various procedures to monitor their response to the investigational medication. These procedures will help researchers assess the medication's effectiveness and identify any potential side effects. Participants will be closely monitored throughout the study.
- Who can participate: Adults with relapsed or refractory hematologic malignancies, who have a life expectancy of at least 3 months, and meet specific health criteria, such as adequate bone marrow, renal, and liver function, and an ECOG Performance status of 0 or 1, may be eligible. Participants must not have certain other health conditions or have received specific prior treatments.
- Study details: Participants will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine. The study will monitor the participants' health and response to the treatment.
How understandable was the trial content above?
Hard to understand
Easy to understand
